Linaclotide: A novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome

Brian E. Lacy, John Levenick, Michael D. Crowell

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Chronic constipation and irritable bowel syndrome (IBS) are functional gastrointestinal disorders that significantly affect patients' quality of life. Chronic constipation and IBS are prevalent-12% of the US population meet the diagnostic criteria for IBS, and 15% meet the criteria for chronic constipation- and these conditions negatively impact the healthcare system from an economic perspective. Despite attempts at dietary modification, exercise, or use of over-the-counter medications, many patients have persistent symptoms. Alternative treatment options are limited. This article describes linaclotide (Linzess, Ironwood Pharmaceuticals/Forest Pharmaceuticals), a new, firstin- class medication for the treatment of chronic constipation and constipation-predominant IBS.

Original languageEnglish (US)
Pages (from-to)653-660
Number of pages8
JournalGastroenterology and Hepatology
Volume8
Issue number10
StatePublished - Oct 2012

Fingerprint

Irritable Bowel Syndrome
Constipation
Diet Therapy
Therapeutics
Gastrointestinal Diseases
Pharmaceutical Preparations
Economics
Quality of Life
linaclotide
Exercise
Delivery of Health Care
Population

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

@article{348ed7a558ac4d8083cb31ed9793f80e,
title = "Linaclotide: A novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome",
abstract = "Chronic constipation and irritable bowel syndrome (IBS) are functional gastrointestinal disorders that significantly affect patients' quality of life. Chronic constipation and IBS are prevalent-12{\%} of the US population meet the diagnostic criteria for IBS, and 15{\%} meet the criteria for chronic constipation- and these conditions negatively impact the healthcare system from an economic perspective. Despite attempts at dietary modification, exercise, or use of over-the-counter medications, many patients have persistent symptoms. Alternative treatment options are limited. This article describes linaclotide (Linzess, Ironwood Pharmaceuticals/Forest Pharmaceuticals), a new, firstin- class medication for the treatment of chronic constipation and constipation-predominant IBS.",
author = "Lacy, {Brian E.} and John Levenick and Crowell, {Michael D.}",
year = "2012",
month = "10",
language = "English (US)",
volume = "8",
pages = "653--660",
journal = "Gastroenterology and Hepatology",
issn = "1554-7914",
publisher = "Gastro-Hep Communications, Inc.",
number = "10",

}

Linaclotide : A novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome. / Lacy, Brian E.; Levenick, John; Crowell, Michael D.

In: Gastroenterology and Hepatology, Vol. 8, No. 10, 10.2012, p. 653-660.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Linaclotide

T2 - A novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome

AU - Lacy, Brian E.

AU - Levenick, John

AU - Crowell, Michael D.

PY - 2012/10

Y1 - 2012/10

N2 - Chronic constipation and irritable bowel syndrome (IBS) are functional gastrointestinal disorders that significantly affect patients' quality of life. Chronic constipation and IBS are prevalent-12% of the US population meet the diagnostic criteria for IBS, and 15% meet the criteria for chronic constipation- and these conditions negatively impact the healthcare system from an economic perspective. Despite attempts at dietary modification, exercise, or use of over-the-counter medications, many patients have persistent symptoms. Alternative treatment options are limited. This article describes linaclotide (Linzess, Ironwood Pharmaceuticals/Forest Pharmaceuticals), a new, firstin- class medication for the treatment of chronic constipation and constipation-predominant IBS.

AB - Chronic constipation and irritable bowel syndrome (IBS) are functional gastrointestinal disorders that significantly affect patients' quality of life. Chronic constipation and IBS are prevalent-12% of the US population meet the diagnostic criteria for IBS, and 15% meet the criteria for chronic constipation- and these conditions negatively impact the healthcare system from an economic perspective. Despite attempts at dietary modification, exercise, or use of over-the-counter medications, many patients have persistent symptoms. Alternative treatment options are limited. This article describes linaclotide (Linzess, Ironwood Pharmaceuticals/Forest Pharmaceuticals), a new, firstin- class medication for the treatment of chronic constipation and constipation-predominant IBS.

UR - http://www.scopus.com/inward/record.url?scp=84868030495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868030495&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84868030495

VL - 8

SP - 653

EP - 660

JO - Gastroenterology and Hepatology

JF - Gastroenterology and Hepatology

SN - 1554-7914

IS - 10

ER -